Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Jonathan L. Guarino net worth and biography

Jonathan Guarino Biography and Net Worth

CFO of Soligenix

Jonathan Guarino has over 20 years of diverse experience in the financial and strategic management of emerging growth and commercial companies, including in the life sciences industry. Previously, he served as Corporate Controller for Hepion Pharmaceuticals, Inc. (formerly ContraVir Pharmaceuticals, Inc.), a New Jersey-based public biotechnology company, where he contributed to the establishment of the financial infrastructure, as well as assisted with capital fund-raising and debt financings. Previously, he worked as Controller and senior manager of technical accounting for Suite K Value Added Services LLC and Covance, Inc. Prior to these positions, he held accounting and finance positions of increasing importance with several companies, including PricewaterhouseCoopers LLP, BlackRock, Inc. and Barnes & Noble, Inc. Mr. Guarino is a CPA (certified public accountant) and CGMA (chartered global management accountant), who received his BS in Business from Montclair State University.

How old is Jonathan L. Guarino?: Mr. Guarino is currently 51 years old. There are 3 older executives and no younger executives at Soligenix. The oldest executive at Soligenix is Dr. Richard C. Straube M.D., MSc., Senior VP & Chief Medical Officer, who is 72 years old. Learn More on Jonathan L. Guarino's age.
How do I contact Jonathan L. Guarino?: The corporate mailing address for Mr. Guarino and other Soligenix executives is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. Soligenix can also be reached via phone at (609) 538-8200 and via email at [email protected]. Learn More on Jonathan L. Guarino's contact information.
Has Jonathan L. Guarino been buying or selling shares of Soligenix?: Jonathan L. Guarino has not been actively trading shares of Soligenix during the last ninety days. Most recently, on Wednesday, December 15th, Jonathan L. Guarino bought 1,000 shares of Soligenix stock. The stock was acquired at an average cost of $0.70 per share, with a total value of $700.00. Learn More on Jonathan L. Guarino's trading history.
Who are Soligenix's active insiders?: Soligenix's insider roster includes Jonathan Guarino (CFO), Christopher Schaber (CEO), and Jerome Zeldis (Director). Learn More on Soligenix's active insiders.

Jonathan L. Guarino Insider Trading History at Soligenix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/15/2021	Buy	1,000	$0.70	$700.00

Jonathan L. Guarino Buying and Selling Activity at Soligenix

Soligenix Company Overview

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $0.38

$0.38

$0.41

50 Day Range

MA: $0.62

$0.39

$0.82

2 Week Range

Now: $0.38

$0.37

$4.20

Volume

491,661 shs

Average Volume

2,994,521 shs

Market Capitalization

$3.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81